Cannabis Companies Face Lawsuits Over Mental Health Claims
In the United States, “unsubstantiated health claims” are the leading cause of consumer protection lawsuits against cannabis brands.
The American cannabis industry is currently navigating a significant legal shift as a wave of consumer protection lawsuits targets major operators. These legal actions center on marketing strategies that allegedly cross the line from general wellness-oriented branding into specific, unsubstantiated mental health claims.
As tensions grow between state-legal cannabis markets and limited federal oversight, the industry faces increasing scrutiny over how products are marketed to vulnerable populations.
Which Cannabis Companies Are Facing Lawsuits?
As of May 2026, a number of leading cannabis multistate operators (MSOs) have come under legal scrutiny through class-action lawsuits claiming they promoted cannabis products as medically beneficial despite alleged health risks.
Filed in federal courts in both Illinois and Connecticut, the complaints allege that these companies marketed cannabis as safe and therapeutic despite research suggesting potential mental health risks, including the worsening of conditions such as anxiety and depression.
Some of the companies that face allegations include Cresco Labs, Green Thumb Industries, Verano Holdings, and Curaleaf Holdings.
The lawsuit filed in federal court in Illinois represents consumers across 12 states and could ultimately expand to include millions of claimants. With potential outcomes ranging from substantial civil fines and punitive damages to allegations resembling civil RICO-style claims, the legal and financial implications could be far-reaching.
Observers familiar with the case have compared the allegations—particularly claims of widespread industry misinformation surrounding a commonly used substance—to the legal strategy once employed against the tobacco industry three decades ago.
The Core of the Litigation: Wellness vs. Medical Claims
The crux of recent class-action filings rests on the distinction between “structure-function” claims and “disease” claims. Under FDA-style advertising principles that many regulators reference, companies can suggest a product “supports a sense of calm.”
However, claiming a product “treats clinical anxiety” or “cures PTSD” without FDA-approved clinical trials moves the product into the category of an unapproved new drug.
Plaintiffs argue that by marketing high-THC products as solutions for complex mental health conditions, companies are engaging in deceptive business practices.
These lawsuits frequently cite limited clinical evidence supporting the specific dosages and formulations promoted for mental health conditions.
The Regulatory Vacuum and Consumer Safety
Broader concerns about cannabis health marketing have also intensified due to the rapid growth of loosely regulated hemp-derived cannabinoid products.
A significant portion of this legal friction stems from the “2018 Farm Bill” loophole, which allowed cannabinoids like Delta-8 and Delta-9 THC to be sold online and in smoke shops with minimal oversight.
Unlike the highly regulated “Rec Market” or “MMJ” (Medical Marijuana) dispensaries, it is not uncommon for these products to reach shelves alongside unsubstantiated medical claims that have drawn criticism from both the FDA and the FTC.
From a public health perspective, the concern is twofold:
- Substitution Risk: Consumers may choose cannabis over proven, evidence-based psychiatric treatments.
- Safety Profiles: For some individuals, particularly those with a history of psychosis, high-potency THC can exacerbate rather than alleviate mental health symptoms.
Could These Lawsuits Have Wider Industry Implications?
These lawsuits are likely to trigger a broader “standardization” phase across the industry. We may begin to see:
- Stricter Labeling: A move away from medicalized language in recreational branding.
- Mandatory Disclaimers: More prominent warnings regarding mental health risks on packaging.
- Third-Party Verification: Increased reliance on independent clinical data before making any health-related marketing claims.
For stakeholders in the US cannabis business, the message is increasingly clear: the industry may be entering a more tightly scrutinized marketing environment, where the legal risks associated with unsubstantiated health claims could outweigh the marketing benefits.
Read more from Soft Secrets:
Disclaimer: The information in this article is for journalistic purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical or mental health condition.
S
Stephen Andrews
